Atai Life Sciences N.V. (NQ: ATAI )

11.14 USD +0.22 (+2.01%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 2, 2021 Add to My Watchlist

Price and Volume

Volume	472,818
Open	10.76
Bid (Size)	10.88 (1)
Ask (Size)	11.27 (67)
Prev. Close	10.92
Today's Range	10.76 - 11.92
52wk Range	10.45 - 22.91
Shares Outstanding	N/A
Dividend Yield	53.86%

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Use of Ketamine for Mental Disorders Rising While New Therapies Emerge

November 17, 2021

Increasing Prevalence of Depression & Mental Health Disorders Fueling Huge Growth in Psychedelic Drugs Market

November 04, 2021

Performance

YTD	-42.72%	-42.72%
1 Month	-28.22%	-28.22%
3 Month	-33.81%	-33.81%
6 Month	-42.72%	-42.72%
1 Year	-42.72%	-42.72%

More News

Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention

October 27, 2021

Analyst Ratings For ATAI Life Sciences

November 30, 2021

Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass Pathways

November 29, 2021

NetworkNewsAudio – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Offers Hope on the Smoking-Cessation Horizon

November 04, 2021

Both Marijuana & Psychedelic Compounds-Based Drug Stocks Indexes Declined Sharply In November

December 01, 2021

Breaking the Habit: Psychedelic Stigma Fades as Research Points to Critical Use in Smoking Cessation and More

November 01, 2021

Analyst Ratings For ATAI Life Sciences

November 11, 2021

Psychedelic Drug Stocks Continued To Decline Last Week

November 21, 2021

Psychedelic Drug Stocks Have Plunged -10.6%, On Average, So Far In November

November 14, 2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.